Nanox Imaging has received the CE Mark to market its Nanox.ARC 3D digital tomosynthesis system, including Nanox.CLOUD, its accompanying cloud-based infrastructure.
The Nanox.ARC stationary x-ray system, which uses digital multisource tomosynthesis technology with a cold cathode to generate a sliced three-dimensional view of the body, received U.S. Food and Drug Administration (FDA) 510(k) clearance in December 2024.
Nanox.ARC is intended for use on adult patients in healthcare facilities or radiological environments. The Israel-based vendor is currently conducting clinical trials to assess the Nanox.ARC at multiple sites, and it will present new data validating the Nanox.ARC at ECR 2025 in Vienna from 26 February to 2 March.
The company noted that it will present data across three abstracts, consisting of a clinical study evaluating digital tomosynthesis for musculoskeletal imaging, a phantom study assessing the impact of obesity on chest imaging, and a case series demonstrating key applications in musculoskeletal diagnostics.
